Eris Lifesciences Limited announced that its Board of Directors met on October 26, 2026, to approve the Unaudited Standalone and Consolidated Financial Results for the quarter and half-year ended September 30, 2026. The results, along with the limited review reports, have been duly approved and taken on record by the board.
Board Meeting Concludes
On October 26, 2026, Eris Lifesciences Limited convened a meeting of its Board of Directors. During this meeting, the board reviewed and approved the Unaudited Standalone and Consolidated Financial Results for the quarter and half-year that concluded on September 30, 2026. The meeting commenced at 11:00 A.M. and concluded at 01:40 P.M.
Financial Reporting
The company has submitted the said financial results, accompanied by a limited review report, as required by SEBI Listing Regulations. These review reports have been issued with an unmodified opinion, confirming the accuracy of the financial statements. Details as per Regulation 52(4) of SEBI Listing Regulations are also included.
Key Financial Figures (Consolidated)
Quarter Ended September 30, 2026
- Total Revenue from Operations: ₹892.37 Crore
- Profit Before Tax: ₹155.91 Crore
- Net Profit: ₹187.14 Crore
Half Year Ended September 30, 2026
- Total Revenue from Operations: ₹1,765.62 Crore
- Profit Before Tax: ₹335.40 Crore
- Net Profit: ₹330.46 Crore
Key Financial Figures (Standalone)
Quarter Ended September 30, 2026
- Total Revenue from Operations: ₹482.24 Crore
- Profit Before Tax: ₹83.51 Crore
- Net Profit: ₹129.15 Crore
Half Year Ended September 30, 2026
- Total Revenue from Operations: ₹971.86 Crore
- Profit Before Tax: ₹147.66 Crore
- Net Profit: ₹177.46 Crore
Source: BSE
